سعر كيلفر 500مجم 50 كبسولة 2025

Kelfer: deferiprone 500 mg capsules, 50 capsules (5 strips) (Cipla Ltd., India; Star International Company, Egypt), an oral iron chelator.

• US label: transfusional iron overload in adults and children 8 years and older with thalassaemia syndromes, sickle cell disease or other anaemias (not established for myelodysplastic syndrome or Diamond-Blackfan anaemia).DailyMed (U.S. National Library of Medicine)
• Directory text: oral iron chelator used as a second-line agent in thalassaemia syndromes with transfusional iron overload.

• Most common (6% or more): nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia; agranulocytosis is the most serious.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to deferiprone or excipients (Henoch-Schönlein purpura, urticaria and periorbital oedema with rash have been reported).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning (US): deferiprone can cause agranulocytosis that can lead to serious infections and death; neutropenia may precede it. Interrupt therapy if neutropenia or infection develops; patients must report symptoms of infection immediately.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Liver enzyme (ALT) elevations, decreased plasma zinc and embryo-fetal toxicity; females of reproductive potential should use effective contraception.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Drugs associated with neutropenia or agranulocytosisAvoid co-administration; if unavoidable, closely monitor the absolute neutrophil count.DailyMed (U.S. National Library of Medicine)
• UGT1A6 inhibitors (e.g. diclofenac, probenecid, silymarin)Avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• Polyvalent cations (iron, aluminium, zinc; e.g. antacids, mineral supplements)Allow at least 4 hours between deferiprone and these products.DailyMed (U.S. National Library of Medicine)

• Animal studies showed structural abnormalities and embryo-fetal death at doses below human exposure; human data are insufficient; deferiprone can cause fetal harm.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Deferiprone: Bidentate ligand that binds iron in a 3:1 (deferiprone:iron) molar ratio, promoting iron excretion (EU SmPC 5.1).